Adage Capital Partners Gp, L.L.C. I Mab Transaction History

Adage Capital Partners Gp, L.L.C.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$8.27 - $18.43 $4.14 Million - $9.22 Million	-500,000 Reduced 35.71%	900,000 $10.2 Million
Q4 2021 Feb 14, 2022	BUY	$45.28 - $74.5 $9.06 Million - $14.9 Million	200,094 Added 16.68%	1,400,000 $66.3 Million
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $21.4 Million - $31.7 Million	375,000 Added 45.46%	1,199,906 $87 Million
Q2 2021 Aug 16, 2021	SELL	$47.86 - $83.95 $18.8 Million - $32.9 Million	-391,788 Reduced 32.2%	824,906 $69.3 Million
Q1 2021 May 17, 2021	SELL	$44.38 - $63.97 $8.33 Million - $12 Million	-187,606 Reduced 13.36%	1,216,694 $59 Million
Q4 2020 Feb 16, 2021	BUY	$32.94 - $47.15 $7.39 Million - $10.6 Million	224,228 Added 19.0%	1,404,300 $66.2 Million
Q3 2020 Nov 16, 2020	BUY	$27.46 - $47.03 $1.72 Million - $2.95 Million	62,755 Added 5.62%	1,180,072 $55.5 Million
Q2 2020 Aug 14, 2020	BUY	$13.0 - $31.0 $1.53 Million - $3.64 Million	117,317 Added 11.73%	1,117,317 $33.4 Million
Q1 2020 May 15, 2020	BUY	$10.63 - $15.37 $10.6 Million - $15.4 Million	1,000,000 New	1,000,000 $13 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $77.3M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.